<DOC>
	<DOC>NCT01022060</DOC>
	<brief_summary>The purpose of this study is to determine whether Renalof administration promotes partial or total dissolution of urinary calculi and improves physicochemical parameters and metabolic activity in patients with recurrent calcic urolithiasis. The duration of this double-blind placebo controlled phase 3 clinical trial will be 12 weeks. The estimated number of patients to be recruited and randomized for the study is 110. Ultrasonographic and humoral parameters will be assessed every 4 weeks.</brief_summary>
	<brief_title>Renalof in the Dissolution of Renal Calculi in Patients With Recurrent Calcic Lithiasis</brief_title>
	<detailed_description />
	<mesh_term>Calculi</mesh_term>
	<mesh_term>Urolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Lithiasis</mesh_term>
	<criteria>Idiopathic calcic lithiasis Calculus size lesser than or equal to 2.0 cm (0.79 inches) Signed informed consent Calculus size greater than 2,0 cm (0.79 inches) Pregnancy Malignant neoplastic conditions Previous treatment for destruction of calculi in the urinary tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Dietary supplement</keyword>
	<keyword>Renalof</keyword>
	<keyword>Recurrent calcic urolithiasis</keyword>
	<keyword>Renal calculi</keyword>
</DOC>